HIV/AIDS
Studies by X. Badia and co-authors describe new findings in HIV/AIDS
Published in AIDS Weekly, October 29th, 2007
According to a study from Barcelona, Spain, "' Fuzeon (enfuvirtide) (ENF) is the first drug among the HIV fusion inhibitors that has shown high efficacy in HIV-1/AIDS patients resistant to conventional antiretroviral agents. To analyze the cost-effectiveness of ENF plus optimized therapy (OT) in HIV patients. A Markov model was used to calculate the cost-effectiveness of ENF in terms of incremental cost per life-year gained. The model has a 10-year horizon, with monthly cycles, and the perspective is the Spanish National Health System."
"Efficacy rates and transition probabilities were obtained from clinical and epidemiological trials. Resource use data were retrieved...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2007-10-29)
More Articles from AIDS Weekly
- HIV/AIDS
High-Risk Individuals Less Likely to Follow Through on HIV Testing Plans - HIV/AIDS
HIV linked to increased risk of ESRD in African-Americans - HIV/AIDS
HIV-Infected Children in Africa Who Receive Care in Primary Health Care Pediatric Treatment Programs Can Have Good Outcomes - HIV/AIDS
39 Noted Performing Artists Urge Congress to Fix Flaws in President's Global AIDS Plan - HIV/AIDS
AHF Challenges Merck Over Steep Price of Its New AIDS Drug, Isentress - HIV/AIDS
Cohen Design Centers Sponsor the AIDS Walks in Los Angeles, Houston, Fort Lauderdale and New York - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
